From St. Louis to Beijing: AD Biomarkers Change Similarly Before Symptoms

In the more than a decade since scientists at Washington University and the Mayo Clinic first proposed the now well-known curves of biomarker change over the course of Alzheimer's disease, researchers have filled in this framework with dozens of fluid and imaging biomarkers that reflect different aspects of AD progression. Data came mostly from cross-sectional, short-term, or familial AD cohorts. Now, two studies have deployed other methods to trace biomarkers longitudinally over the course of sporadic AD. They report surprisingly similar trajectories, which largely confirm prior analyses.